Chicago, IL, United States
Meitheal Pharmaceuticals Inc recalls
3 recalls recorded since 2018, most recently on 9 February 2026. 1 is listed as ongoing. Status and classification are as published by the FDA.
Recalls3
Ongoing (FDA)1
Terminated or completed2
Class I (FDA)1
Ongoing Class II Drugs
- Recall started
- 9 February 2026
- Reason
- Defective Delivery System: Missing or duplicated needles within the injection kit
- Distribution
- U.S. Nationwide
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-0340-2026
- Cetrorelix Acetate for Injection (Kit), 0.25 mg per vial, Single-Dose Kit, Rx Only, Mfd. for: Meitheal Pharmaceuticals, Chicago, IL NDC 71288-558-90.
Terminated Class III Drugs
- Recall started
- 3 September 2021
- Terminated
- 12 May 2024
- Reason
- Failed Impurities/Degradation Specifications
- Distribution
- Nationwide within the USA and India
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-0801-2021
- Glycopyrrolate Injection, USP 4mg per 20mL, 20 mL Multi-Dose Vials, Rx only, Mfd for Meitheal Pharmaceuticals, Chicago, IL 60631. NDC 71288-408-21
Terminated Class I Drugs
- Recall started
- 27 January 2021
- Terminated
- 16 October 2023
- Reason
- Labeling: Label mix-up: Carton of Cisatracurium Besylate Injection, USP was observed to contain ten vials mislabeled as Phenylephrine Hydrochloride Injection, USP, but confirmed to contain Cisatracurium
- Distribution
- Nationwide USA
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-0286-2021
- Cisatracurium Besylate Injection, USP, 10mg per 5mL (2 mg per mL), Single-Dose Vial (NDC 71288-712-05), packaged as 10 x 5 mL Single-Dose Vials per carton (NDC 71288-712-06), Rx only, Mfd. for Meitheal Pharmaceuticals,
A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.